Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18705
Abstract: e18705Background: Germline testing guidelines are centered on BRCA1 and BRCA2 despite clear medical management recommendations in several other high and moderate penetrance genes. Clinician utiliza... read more here.
Keywords: reported utility; clinician reported; utility years; years post ... See more keywords